Furthermore, clinical-pharmacogenetic model for prediction of time to occurrence of dyskinesia included female sex (HR = 1.07), age at diagnosis (HR = 0.97), tremor-predominant Parkinson's disease (HR = 0.88), beta-blockers (HR = 0.95), alcohol consumption (HR = 0.99), time from diagnosis to initiation of levodopa treatment (HR = 1.15), <i>CAT</i> rs1001179 (HR = 1.27), <i>SOD2</i> rs4880 (HR = 0.95), <i>NOS1</i> rs2293054 (HR = 0.99), <i>COMT</i> rs165815 (HR = 0.92), and <i>SLC22A1</i> rs628031 (HR = 0.80).
Together, carrying allele G in the single nucleotide polymorphism (rs2070424 A/G) in SOD1, or allele C in the single nucleotide polymorphism (rs4880 T/C) in SOD2, enhances genetic susceptibility to Parkinson's disease.